Japan's Daiichi Sankyo halts trials of existing drug for COVID-19 treatment

Health News

TOKYO (Reuters) – Japan’s Daiichi Sankyo Co said on Tuesday it was halting development of an existing drug for the treatment of COVID-19.

Daiichi Sankyo in March started a clinical trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients. The company said in a statement it was discontinuing the trial without citing a reason. The Nikkei newspaper reported that there were safety concerns.

Nafamostat is used in the treatment of pancreatitis and has antiviral properties.

Source: Read Full Article

Related posts:
  1. The quantum brain: What a laser can tell us about the relationship between entangled photons and neurons
  2. Biden pledges free Covid vaccine for ‘everyone’ in US if elected
  3. Delaying the second COVID vaccine dose: A medical expert answers key questions
  4. Why telling stories could be a more powerful way of convincing some people to take a COVID vaccine than just the facts
  5. Taiwan's new COVID-19 cases slow, but curbs to stay in coming weeks